


PHARMACEUTICAL 2022

Regen BioPharma Inc Rank 421 of 475





PHARMACEUTICAL 2022

Regen BioPharma Inc Rank 421 of 475

The relative strengths and weaknesses of Regen BioPharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regen BioPharma Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 1,212% points. The greatest weakness of Regen BioPharma Inc is the variable Other Net Income, reducing the Economic Capital Ratio by 324% points.

The company's Economic Capital Ratio, given in the ranking table, is -532%, being 255% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	994
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,698
Liabilities, Non-Current	0
Other Assets	218
Other Compr. Net Income	0
Other Expenses	216
Other Liabilities	0
Other Net Income	-6,454
Property and Equipment	0
Research and Development	37
Revenues	61
Selling, General and Administrative Expense	119

Output Variable	Value in 1000 USD
Assets	1,212
Liabilities	14,698
Expenses	372
Stockholders Equity	-13,486
Net Income	-6,765
Comprehensive Net Income	-6,765
Economic Capital Ratio	-532%